"Xeljanz (Tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis ... SBWire (press release) Pfizer has developed Xeljanz (tofacitinib;formerly known as tasocitinib), an oral, small-molecule inhibitor of JAK3 kinase for the treatment of RA, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, transplant ... |
